HORIZON EUROPE
European
Specific Challenge:Hematologic malignancies (HMs) account for about one-third of cancer cases in children and about one-third of cancer deaths. Due to the rarity of the conditions and the diverse healthcare practice across EU, current healthcare systems are challenged with
lack of definition and alignment on outcomes policy makers having limited benchmark data to evaluate the risk/benefit ratio and value, clinicians having to make treatment choices based on short-term, surrogate and often not comparable data payers having the need to make reimbursement decisions on life prolonging options with limited data and finite budgets. This can lead to patients not having access to the right treatment at the right time.
Scope:Key objectives include:
define standard sets of outcomes for HMs that are relevant and meaningful to patients and clinicians communicate and support the use of the defined standard outcomes data sets on selected HMs develop a data sharing platform that empowers clinicians and policy stakeholders to improve decision making propel key medical and policy initiatives through fact based decisions based on large, diverse...
see more
Specific Challenge:Hematologic malignancies (HMs) account for about one-third of cancer cases in children and about one-third of cancer deaths. Due to the rarity of the conditions and the diverse healthcare practice across EU, current healthcare systems are challenged with
lack of definition and alignment on outcomes policy makers having limited benchmark data to evaluate the risk/benefit ratio and value, clinicians having to make treatment choices based on short-term, surrogate and often not comparable data payers having the need to make reimbursement decisions on life prolonging options with limited data and finite budgets. This can lead to patients not having access to the right treatment at the right time.
Scope:Key objectives include:
define standard sets of outcomes for HMs that are relevant and meaningful to patients and clinicians communicate and support the use of the defined standard outcomes data sets on selected HMs develop a data sharing platform that empowers clinicians and policy stakeholders to improve decision making propel key medical and policy initiatives through fact based decisions based on large, diverse harmonised data sets.
Expected Impact:Improved clinical development based on clear definition of endpoints, outcome measures leading to consistent assessments across EU;
better understanding of the natural history of the diseases; ability to prove the value, safety and effectiveness of therapies, therefore faster patient access to these therapies.
see less
Consortium characteristics
:
The aid is European, you can apply to this line any company that is part of the European Community.
characteristics of the Proyecto
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Characteristics of financing
The budget breakdown for this call is given at the end of the Call topics text, in the Call Conditions section, as well as the following information :
List of countries and applicable rules for funding
Eligibility and admissibility conditions
Evaluation criteria and procedure, scoring and threshold: described in the IMI2 Manual for submission, envaluation and grant award
Indicative timetable for evaluation and grant agreement
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):
Summary of the most relevant provisions for participating in IMI2 actions
Standard proposal template
Standard evaluation form
IMI2 Model Grant Agreement
Template for essential clinial trial information
Please read carefully all provisions below before the preparation of your application.
The budget breakdown for this call is given at the end of the Call topics text, in the Call Conditions section, as well as the following information :
List of countries and applicable rules for funding
Eligibility and admissibility conditions
Evaluation criteria and procedure, scoring and threshold: described in the IMI2 Manual for submission, envaluation and grant award
Indicative timetable for evaluation and grant agreement
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):
Summary of the most relevant provisions for participating in IMI2 actions
Standard proposal template
Standard evaluation form
IMI2 Model Grant Agreement
Template for essential clinial trial information
Additional information about the call
other advantages
